Skip to content

Earnings call

Sun Pharmaceutical Industries Q3 FY25 earnings call

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

Consolidated Q3 FY '25 sales were INR 134,369 million, an increase of 10.5% versus Q3 FY '24; excluding milestone income in ROW, overall sales growth was 8.9%. Sun Pharma was ranked number 1 and held 8.2% market share in the over INR 2,214 billion Indian pharmaceutical market as per AIOCD AWACS MAT December 2024; the corresponding market share for the previous period was 7.8%. The company launched 4 generic products in the U.S. in Q3 FY '25. Net cash was US$ 3 billion at the consolidated level as of 31st December 2024.

The numbers management gave

Results

  • Consolidated Q3 FY '25 sales were INR 134,369 million, an increase of 10.5% versus Q3 FY '24; excluding milestone income in ROW, overall sales growth was 8.9%.
    Show source
    Q3 FY '25 sales were at INR 134,369 million, an increase of 10.5% versus Q3 FY '24.
  • Material cost was 20.4% of sales in Q3 FY '25, lower than the same period last year due to milestone income and better product mix, including higher specialty sales.
    Show source
    Material cost stands at 20.4% of sales, lower than the same period last year on account of milestone income as well as better product mix, including higher specialty sales.
  • Staff cost was 19% of sales in Q3 FY '25.
    Show source
    Staff cost stands at 19% of sales.
  • Other expenses were 31.2% of sales in Q3 FY '25, lower year-on-year due to lower R&D and selling and distribution expenses.
    Show source
    Other expenses were at 31.2% of sales, lower year-on- year on account of lower R&D and lower selling and distribution expenses.
  • Other expenses were lower quarter-on-quarter in absolute terms in Q3 FY '25 due to lower selling and distribution expenses.
    Show source
    Other expenses were also lower quarter-on- quarter in absolute terms on account of lower selling and distribution expenses.
  • The company had a forex loss of INR1,834 million in Q3 FY '25, compared to a gain of INR 1,246 million in the same period last year.
    Show source
    Forex loss for the quarter was INR1,834 million compared to a gain of INR 1,246 million same period last year.
Show 25 more statements

Results

  • EBITDA, including other operating revenues, was INR40,090 million in Q3 FY '25, an increase of 15.3% over Q3 last year; EBITDA margins were 29.3%, against 28.1% for Q3 FY '24 and 29.6% for Q2 FY '25.
    Show source
    EBITDA, including other operating revenues, was Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.c om, Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY25 Earnings Call Transcript 06:30 pm January 31, 2025 at INR40,090 million for Q3, an increase of 15.3% over Q3 last year, with EBITDA margins for the quarter at 29.3% against 28.1% for Q3 FY '24 and 29.6% for Q2 FY '25.
  • The exceptional item of INR 3,162 million in Sun Pharmaceutical Industries Limited’s Q3 FY '25 results related to an in principle agreement of a settlement with certain plaintiffs in the U.S. in the opioid litigation.
    Show source
    We had an exceptional item in Q3 FY '25 amounting to INR 3,162 million.
  • Adjusted net profit, excluding exceptional items, was INR 32,196 million in Q3 FY '25, representing growth of 24.1% over Q3 FY '24.
    Show source
    Adjusted net profit, excluding exceptional items, for Q3 FY '25 was INR 32,196 million, representing a growth of 24.1% over Q3 FY '24.
  • Reported net profit was INR 29,034 million in Q3 FY '25, compared with INR25,238 million in Q3 FY '24.
    Show source
    Reported net profit for Q3 FY '25 stands at INR 29,034 million as against reported net profit of INR25,238 million in Q3 FY '24.
  • Effective tax rate was 14.7% in Q3 FY '25.
    Show source
    The effective tax rate for Q3 FY '25 was 14.7%.
  • EPS was INR 13.4 per share in Q3 FY '25.
    Show source
    EPS for the quarter was INR 13.4 per share.
  • Material cost was 20.7% of sales for the 9 months, lower than 9 months last year mainly due to product mix, including higher specialty sales.
    Show source
    Material cost for 9 months was at 20.7% of sales lower than 9 months last year, mainly due to product mix, including higher specialty sales.Staff cost stands at 19.1% of sales.
  • The company had a forex loss of INR 1,057 million for the 9 months, compared to a gain of INR 925 million for the same period last year.
    Show source
    Forex loss for 9 months was INR 1,057 million compared to a gain of INR 925 million for the same period last year.
  • EBITDA was INR 115,556 million for the 9 months, a growth of 15.7% over the 9 months last year, with EBITDA margins of 29.2%.
    Show source
    EBITDA for 9 months was at INR 115,556 million, a growth of 15.7% over the 9 months last year, with resultant EBITDA margins of 29.2%.
  • Adjusted net profit for the 9-month period was INR90,953 million, up 24.3%.
    Show source
    Adjusted net profit for the 9-month period was at INR90,953 million, up 24.3%.
  • India formulation sales were INR 43,004 million in Q3 FY '25, recording growth of 13.8% over Q3 last year.
    Show source
    For Q3, the sales of formulation in India were INR 43,004 million, recording a growth of 13.8% over Q3 last year.
  • The company grew higher than IPM for the quarter ending December '24 and performed well across all major represented therapy areas.
    Show source
    For the quarter ending December '24, we grew higher than IPM, and we have done well across all major represented therapy areas.
  • Overall U.S. business sales were US$ 474 million in Q3 FY '25, down by about 1% over Q3 last year; growth in specialty offset the decline in generics.
    Show source
    For Q3, our overall sales in the U.S. business were down by about 1% over Q3 last year, at US$ 474 million.
  • The U.S. accounted for over 30% of Sun Pharmaceutical Industries Limited’s consolidated sales in Q3 FY '25.
    Show source
    The U.S. accounted for over 30% of consolidated sales for the quarter.
  • Lower sales of Lenalidomide in Q3 FY '25 versus Q2 contributed to Sun Pharmaceutical Industries Limited’s quarter-on-quarter sales drop in the U.S. business.
    Show source
    We had lower sales of Lenalidomide in Q3 versus Q2, contributing to the Q-o- Q drop.
  • Revenue in emerging markets was US$ 277 million, up by 10.1% over Q3 last year.
    Show source
    Our revenue in emerging markets were at US$ 277 million, up by 10.1% over Q3 last year.
  • Underlying growth in emerging markets in constant currency terms was 14% year-on-year for Q3.
    Show source
    The underlying growth in constant currency terms was 14% year-on- year for Q3.
  • Major emerging markets performed well in local currency terms in Q3 FY '25.
    Show source
    All our major markets have done well in local currency terms.
  • Global Specialty sales were up by 24.8% to reach US$ 370 million in Q3 FY '25.
    Show source
    Q3 FY '25, our Global Specialty sales were up by 24.8% to reach US$ 370 million.
  • The company reported gross sales of Rs. 392,257 million, growth of 9.1%, for the quarter and nine months ended December 31, 2024.
    Show source
    For the 9 months, gross sales were at INR 392,257 million, a growth of 9.1% over last year.
  • Staff cost was 19.1% of sales in H1.
    Show source
    Material cost for 9 months was at 20.7% of sales lower than 9 months last year, mainly due to product mix, including higher specialty sales.Staff cost stands at 19.1% of sales.
  • Net profit for 9m FY25 was Rs. 87,792 million.
    Show source
    Reported net profit for 9 months was at INR 87,792 million compared to INR 69,218 million in the same period last year.
  • India formulation sales accounted for 32% of Sun Pharmaceutical Industries Limited’s total consolidated sales in Q2 FY ‘25.
    Show source
    India formulation sales accounted for 32% of total consolidated sales for the quarter.

Money and capital

  • Net cash was US$ 3 billion at the consolidated level as of 31st December 2024.
    Show source
    As of 31st December 2024, net cash was US$ 3 billion at the consolidated level.
  • The Board declared an interim dividend of INR 10.50 per share for FY '25, against an interim dividend of INR 8.50 per share for the previous year.
    Show source
    The Board has declared an interim dividend of INR 10.50 per share for the year FY '25 against INR 8.50 per share interim dividend for the previous year.

What it is building and selling

Demand and pricing

  • Sun Pharma was ranked number 1 and held 8.2% market share in the over INR 2,214 billion Indian pharmaceutical market as per AIOCD AWACS MAT December 2024; the corresponding market share for the previous period was 7.8%.
    Show source
    Sun Pharma is ranked number 1 and holds 8.2% market share in the over INR 2,214 billion Indian pharmaceutical market as per AIOCD AWACS MAT December 2024.
  • The underlying business and prescription trend for Sun Pharmaceutical Industries Limited’s key growth brands, including ILUMYA, CEQUA, ODOMZO and WINLEVI, remained strong in Q3 FY '25.
    Show source
    The underlying business and the prescription trend for our key growth brands, including ILUMYA, CEQUA, ODOMZO and WINLEVI remain strong.

Segments

  • The company launched 4 generic products in the U.S. in Q3 FY '25.
    Show source
    For Q3, we launched 4 generic products in the U.S. I will now hand over the call to Mr. Shanghvi.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Kunal Dhamesha: Congratulations on a good set of numbers. The first question, if I look at our recent Specialty deals, these are basically emerging in new therapeutic areas, diverging from our current focus on derma, derma- onco and opthal. So could you clarify whether this shift represents a strategic change? Or these are more opportunistic? How should we think about it?

    Answer, dilip shanghvi

    Dilip Shanghvi: No. I think in our view, there are adjacencies, but at the same point of time have linkage with derma-onc and the specialty even though a little bit different from the one which we'll need to focus on will not require a large field force for us to create as a new team. So we will remain opportunistic, but the focus on dermatology and ophthalmology will continue.

  2. Question

    Kunal Dhamesha: Sure, sir. And the second question is on the specialty growth, which has been quite strong for us. And we have highlighted that ILUMYA, CEQUA, WINLEVI, and ODOMZO have been drivers. But apart from that, would you say some seasonal products like LEVULAN also helped us in this quarter? And if yes, how are the trends panning out in the ongoing quarter?

    Answer, c muralidharan

    C. S. Muralidharan: So the growth in specialty, whether I look at quarter-on- quarter, year-on- year has come from both from U.S. and ex U.S. markets with similar dollar contribution in both the markets. In ex U.S., some inventory build upwere with the partner this quarter. I'll now request Abhay to give more colour on the U.S. Abhay Gandhi: I think you said it rightly, there is a seasonal impact in Q3, which is typically our strongest quarter. I think if you look at it on an annual basis, the underlying business will continue to do well.

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think FDA is expecting us to do some further studies and submit to them for them to evaluate the lift of clinical hold. So we believe that this is an interesting asset, which then can help us not only in the U.S., but also in the current global environment where for treatment of pain opiates are avoided. So it's a good opportunity. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.c om, Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY25 Earnings Call Transcript 06:30 pm January 31, 2025 Shashank Krishnakumar: Got it.

  3. Question

    My second question was on the ex- Taro, ex-REVLIMID generic business. So while I think you alluded to the REVLIMID decline Q-o- Q, but has there also been a meaningful decline sequentially in the ex-Taro ex REVLIMID piece as well?

    Answer, abhishek sharma

    Abhishek Sharma: While Abhay will answer this question, we don't talk about Taro separately,Shashank.

  4. Question

    Shashank Krishnakumar: Yes. Sir, just looking for some qualitative comments.

    Answer, abhay gandhi

    Abhay Gandhi: Ex -REVLIMID,the decline is very, very marginal.

  5. Question

    Bino Pathiparampil: Yes. My first question is on LEQSELVI. Any update on the litigation, what's happening and what is our expected launch time line?

    Answer, dilip shanghvi

    Dilip Shanghvi: So I think we expect the, what you call, oral arguments by sometime -- to begin sometimes in April. And then post that, we'll await the judgment.

  6. Question

    Bino Pathiparampil: Okay. And even if the judgment is against us, the December launch timeline stays intact. Is it?

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think it all depends on what judgment is because we -- if the -- let's say, the judgment is to validate the existing judgment, and we can't launch till the time we get a more favourable judgment.

  7. Question

    Bino Pathiparampil: No, I asked because in a n earlier call, you had mentioned that December that patent under question is expiring, so you could launch after that.

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think that is what you call validity of the patent. So in case of my understanding is that this patent is valid till December of '26. So in case if the judgment is what you call not in our favour . And if we can't get a final judgment earlier than that, then we have to wait till December '26. That's what was my statement.

  8. Question

    Bino Pathiparampil: Understood. Second question on your depreciation and amortization amount. The amount has not grown much year last year also and this year also for 9 months, it's actually a little below last year's run Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.c om, Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY25 Earnings Call Transcript 06:30 pm January 31, 2025 rate. And if I look at your stand- alone depreciation amortization, which has actually substant

    Answer, c muralidharan

    C. S. Muralidharan: So as far as consol depreciation is concerned, there are some assets getting capitalized. Some assets are fully already depreciated. That's one of the reasons you see the fluctuation in the depreciation.

  9. Question

    Bino Pathiparampil: Okay. So the consol is likely to stay like this, not increase significantly unless we add some major assets in the coming years?

    Answer, c muralidharan

    C. S. Muralidharan: Yes. Unless we --as capitalization progresses, depreciation will also increase.

  10. Question

    Bino Pathiparampil: Okay. And the stand- alone depreciation and amortization has come down significantly Q- o- Q, as well as for 9 months. It's from almost INR 400 crores to INR300 crores.

    Answer, c muralidharan

    C. S. Muralidharan: I think there are many entities which comes into the consolidated numbers. It will be appropriate to look at the consolidated depreciation rather than stand- alone.

    Answer, kirti ganorkar

    Kirti Ganorkar: I think as we have said in the past, a majority of our business is a branded generic business. The trade business contribution is almost negligible to our business. So all the growth, what you are seeing, is coming from branded generic business. And in terms of second question, if I understand correctly, you are asking about the field force. So we have already told in March '24, our total field force was 14,000 people on the ground. Yes.

Show 19 more questions
  1. Question

    Neha Manpuria: And any plans to expand that, sir?

    Answer, kirti ganorkar

    Kirti Ganorkar: So at the end of the year, that is -- after quarter 4, we will let you know about our expansion plans, yes.

  2. Question

    Neha Manpuria: Okay. Got it. My second question is on R&D. Mr. Shanghvi, you mentioned that there's been delay in clinical trials because of which we are lowering our guidance. And that's been through the year, we've seen that guidance being lower. What are the key reasons for the delay in the trials? And does this delay -- because Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.c om, Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY25 Earnings Call Transcript 06:30 pm

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think it's taken us a little bit longer to finalize the protocols. And then we are waiting for the final bids as well as approval so that the studies can start.

  3. Question

    Neha Manpuria: In that case, would there be a risk to some of these milestones that we have mentioned, given there have been a few quarters of delay?

    Answer, dilip shanghvi

    Dilip Shanghvi: The milestones are if we have to pay out. No, I think what we are now talking to the CRO is that how do we find a way to accelerate the study by both increasing the number of study sites as well as the number of countries in which we will do the study.

  4. Question

    Anubhav Agarwal: First, a clarity on what Murali sir talked about. One, on the specialty side, when you said that sequentially, half has come from ex U.S. and half has come from U.S. Is that excluding licensing income, milestone income, so let's say, is that current on US$ 286 million going to US$ 325 million that has come half in the U.S., non- U.S. Or you're talking about US$ 286 million going to US$370 million?

    Answer, abhishek sharma

    Abhishek Sharma: It's roughly half ex of milestone income, roughly.

  5. Question

    Anubhav Agarwal: Okay. Second question for Dilip bhai is you made a comment that on the Canada asset, which is in the pain and inflammation space, you may look at it because it doesn't require a large field force. Is this because it's a hospital product? And would that mean that you will be looking at -- willing to look at more hospital products or is this an exception?

    Answer, dilip shanghvi

    Dilip Shanghvi: No. We believe that if approved, this is a product that we can market not only in the U.S. but also in emerging markets where pain continues to be an important component of business, and we have field force which can handle these kind of products.

  6. Question

    Anubhav Agarwal: You mean you already have existing field force in EMs for this? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.c om, Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY25 Earnings Call Transcript 06:30 pm January 31, 2025 Dilip Shanghvi: Correct.

    Answer, dilip shanghvi

    We have -- this field force already visits the doctors. So I think it's both attractiveness of the product for the regulated as well as in emerging markets.

  7. Question

    Anubhav Agarwal: But for this product, largely the like what will be rough split? Is it like hospital usage will be like 70%? Or is it 50%, 50%? What would be split?

    Answer, dilip shanghvi

    Dilip Shanghvi: Yes. No, I think what we are doing is we are trying to focus on, first of all, removing the clinical hold and then identify the set of studies that will help us get to market the fastest. Most likely, what you're saying is what's going to happen is that the initial developed indication will be hospital indications.

  8. Question

    Anubhav Agarwal: Okay. And just if I can ask one more question or if I can join. One comment I wanted, Dilip bhai, from you is that biosimilars now in the U.S. is increasingly moving towards interchangeability now, would you be interested now in looking at the space or it's still a no, no for you?

    Answer, dilip shanghvi

    Dilip Shanghvi: Every quarter, we come back to this question. Hopefully, at some point, we'll take a decision internally. I'm not talking about investor calls, but internally. I think for us, the question is where do we allocate the R&D spend because we have a finite amount of money that we can invest in R&D. So specialty, generics, and then we can also invest in creating a biosimilar pipeline.

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think these are all achievement of certain sales milestones. So linked with the achievement of sales milestones. So I think it's all a function of how well the product continues to do well and whether it touches the next milestone or not.

  9. Question

    Bino Pathiparampil: Okay. So nothing seasonal like in 3Q, it comes?

    Answer, dilip shanghvi

    Dilip Shanghvi: No, no, no. Bino Pathiparampil: Okay.

  10. Question

    Okay. And Dilip bhai, one request if you may consider. Since you have become a very large specialty company now, all the large global specialty companies do give out the sales of individual products, at least the big ones. So it would be great if you can consider that. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.c om, Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY25 Earnings Call Transcript 06:30 pm January 31, 2025 Dilip Shanghvi: No, I think thank you for, firs

    Answer, dilip shanghvi

    But because a large part of our business currently still continues to be the branded generic and generic business. But I think we will -- our focus is to help investors understand both company's current performance and expected future performance in such a way that it also does not create unnecessary pressure on the company and the management. At the same time, investors have a visibility of our future trajectory. So if there is a need for us to relook at something, we will clearly relook at. So thank you.

  11. Question

    Surya Narayan Patra: Sir, in the opening remarks about the India business, you have talked about the lower distribution cost during this quarter or kind of a lowest distribution cost during the quarter. What is the reason for that? And also extended point on the India, you mentioned that the outperformance in the domestic growth against the IPM has been consistent, and that is largely driven by the new launches rather than the price-led rise in the IPM. So given that, is it fair to believe that this outperformance likely to continue for next few quarters since it is like new launch r ate?

    Answer, kirti ganorkar

    Kirti Ganorkar: I think what I said is the growth is coming from volume and new products, both are contributing into the growth compared to IPM where the growth is mostly price-led that is what is -- I said. So for future, it's difficult to predict, but our endeavor is always to grow higher than the market and try to gain market share, yes.

    Answer, dilip shanghvi

    Dilip Shanghvi: Abhay, you want to take that one.

    Answer, abhay gandhi

    Abhay Gandhi: I think the question was on distribution costs for India, Abh ishek.

    Answer, surya patra

    Surya Narayan Patra: This opening commentary was indicating about lower distribution costs in this current quarter. So it would be a kind of a combined cost?

    Answer, abhay gandhi

    Abhay Gandhi: Mr. Patra, you have characterized this far better than I could have, it has been vaguely talked about as of now. So we do not know what will be the final shape. You would also be aware that right now, there are confirmatory hearings on certain key appointees, which hasn't really fructified. The new appointees have not yet taken over their respective functions. So till we actually know certainly what are the actions being taken, difficult for us to plan in advance.

    Answer, surya patra

    Surya Narayan Patra: Sure. Okay. Just one more point, Dilip bhai, about the consumer health business. See in fact having created branded business across the geographies is strongly the consumer business, which has been a kind of old initiatives of us . But it has been kind of a 1 not been highlighted the way it has been highlighted by other peers. So what is the current size? And what is the outlook that you are having?

    Answer, surya patra

    And how progressively or at what growth rate it is kind of moving on. If you can give some sense? And can it be a kind of a contributor to the overall growth of Sun Pharma going ahead.

    Answer, dilip shanghvi

    Dilip Shanghvi: So I think you have a visibility of our India consumer business. What I think you don't have visibility for and we don't also highlight is almost US$200 million worth of consumer business that we have in our emerging market business, which is also OTC kind of products. So it continues to be an important component of our company and growth. Only thing is that since we handle this business more or less the same way like we handle the prescription business, we are not differentiating and sharing the numbers separately. But it continues to be an important component of our growth.

  12. Question

    Kunal Dhamesha: Can you please throw some more light on the inventory buildout that we had suggested for one of the specialty products at our partner end? I am under the impression that whatever we do ex U.S. are generally through partner and we just received royalty in our revenue.

    Answer, dilip shanghvi

    Dilip Shanghvi: We also capture the product sales and the product sales are lumpy.

  13. Question

    Kunal Dhamesha: This is the inventory buildout that we talked about. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.c om, Gaurav Chugh, + 91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q3 FY25 Earnings Call Transcript 06:30 pm January 31, 2025 Dilip Shanghvi: As a partner.

    Answer, dilip shanghvi

    Yes. So if partner buys something then before he -- so every time he buys a reasonably large amount, so he may not buy in the next quarter. That's why we are saying it's lumpy.

  14. Question

    Kunal Dhamesha: So basically when he buys, it triggers royalty payment.

    Answer, dilip shanghvi

    Dilip Shanghvi: Royalty has to be paid independent when he sells.

  15. Question

    Kunal Dhamesha: So let's say when Almirall buys, basically, does it...

    Answer, dilip shanghvi

    Dilip Shanghvi: I will get top line and they will give us monthly statement based on which the royalty is paid. So there may be a different arrangement with different partners.

  16. Question

    Kunal Dhamesha: Sure. And the second question, if I look at our specialty R&D now as a percentage of specialty revenue, excluding milestones, it's coming out to be roughly around 12% of the specialty revenue, right? So generally, what you're seeing with the large innovator company is typically around 16%, 17% range. So how should we think about this going forward? Not just 1 quarter, but let's say, over the next 2, 3 years, how are we thinking about it?

    Answer, dilip shanghvi

    Dilip Shanghvi: I mean that's the focus. And if we would have achieved our guidance, then that is what it would have reached.

  17. Question

    Kunal Dhamesha: Okay, sure. And sir, last one on the capital deployment, which we have a strong cash balance now. And I'm sure that we have been evaluating a lot of deals. But has there been any let's say, change in the end market valuations that you see it has become more attractive, less attractive, the number of deals that we churn or we look at per year, has that increased, decreased? How should we think that?

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think we are open for looking at. I mean, we constantly look at any value-add options. Anything which is strategic and we think we can it will add value to our existing business and is accretive is something that we seriously consider.

  18. Question

    Kunal Dhamesha: But would it be more like specialty or you would also look at India business as well if you find that attractive or something in emerging markets?

    Answer, dilip shanghvi

    Dilip Shanghvi: No, I think generally priority is to focus on specialty products.

  19. Question

    Dilip bhai, I just wanted to check with you on the Japanese portfolio and how we're doing, seeing that the mix of specialty has become almost 50-50 with U.S. and non- U.S. If you could just give some colour on the specialty business in Japan as well as on the Novartis portfolio that we acquired almost over a decade ago now. How has that progressed in Japan?

    Answer, dilip shanghvi

    Dilip Shanghvi: No, first of all, we don't split the specialty in terms of giving numbers. But our focus is on growing the specialty business in Japan because the generic business has become very challenging in terms of pricing and overall attractiveness. So maybe, Kirti, you can respond.

    Answer, kirti ganorkar

    Kirti Ganorkar: Yes. Generic business, what you are referring to, Novartis, long- listed brands, there is a price pressure. Every year, there is a price decrease ranging from 5% to 7%, depending on the product. So our focus is to continue to grow ILUMYA business. ILUMYA,Duac the future pipeline also.

Questions about this call

When was the Sun Pharmaceutical Industries Q3 FY25 earnings call transcript filed?
Sun Pharmaceutical Industries filed the transcript with the exchange on 6 Feb 2025. This page is built from that transcript.
What does this page list?
34 statements from the transcript across 4 topics, 34 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 29 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Sun Pharmaceutical Industries Q3 FY25 concall: what the company said · DalalOS